News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Galapagos Genomics NV Expects 4Q ’05 Revenues To Meet Guidance, Reduced Full Year 2005 Cash Burn
January 18, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Galapagos (Euronext & LSE: GLPG) announced today that it expects fourth quarter 2005 consolidated revenues to meet previous guidance of € 7.7 million, and full year cash burn for 2005 to be lower than guidance of € 7 million.
Twitter
LinkedIn
Facebook
Email
Print
Europe
MORE ON THIS TOPIC
Insights
The Golden Triangle and the gaps: Rethinking UK biotech
June 25, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Insights
Beyond sunshine: Iberia’s biotech moment has arrived with developing capital networks
June 12, 2026
·
4 min read
·
Jennifer C. Smith-Parker
Insights
Portugal, Spain and the new biotech frontier
June 11, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Job Trends
May layoffs hit nearly 7,000, with most cuts from Takeda, BioNTech
June 11, 2026
·
3 min read
·
Angela Gabriel